| 3627- | Cro, | The effects of Crocus sativus (saffron) and its constituents on nervous system: A review |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3628- | Cro, | VitE, | CUR, | Vitamin E, Turmeric and Saffron in Treatment of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3629- | Cro, | Studying saffron nanopowder (Crocus Sativus L.) on the temporal memory of rats suffering Parkinson's disease |
| - | in-vivo, | Park, | NA |
| 3630- | Cro, | Crocin Improves Cognitive Behavior in Rats with Alzheimer's Disease by Regulating Endoplasmic Reticulum Stress and Apoptosis |
| - | in-vivo, | AD, | NA |
| 3631- | Cro, | Investigation of the neuroprotective effects of crocin via antioxidant activities in HT22 cells and in mice with Alzheimer's disease |
| - | in-vitro, | AD, | HT22 | - | in-vivo, | AD, | NA |
| 3634- | Cro, | A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease |
| - | Trial, | AD, | NA |
| 3635- | Cro, | A Review of Potential Efficacy of Saffron (Crocus sativus L.) in Cognitive Dysfunction and Seizures |
| - | Review, | NA, | NA |
| 3637- | Cro, | Investigation of the neuroprotective action of saffron (Crocus sativus L.) in aluminum-exposed adult mice through behavioral and neurobiochemical assessment |
| - | NA, | AD, | NA |
| 3832- | Cro, | Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4158- | Cro, | Antidepressant effects of crocin and its effects on transcript and protein levels of CREB, BDNF, and VGF in rat hippocampus |
| - | in-vivo, | AD, | NA |
| 945- | Cro, | Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Cerv, | HeLa |
| 4208- | Cro, | Antidepressant Effect of Crocus sativus Aqueous Extract and its Effect on CREB, BDNF, and VGF Transcript and Protein Levels in Rat Hippocampus |
| - | in-vivo, | NA, | NA |
| 6527- | CRV, | Preventive effect of D-carvone during DMBA induced mouse skin tumorigenesis by modulating xenobiotic metabolism and induction of apoptotic events |
| - | in-vivo, | Melanoma, | NA |
| 6533- | CRV, | Potential anticancer activity of carvone in N2a neuroblastoma cell line |
| - | in-vitro, | neuroblastoma, | N9 |
| 6532- | CRV, | doxoR, | R-(-)-carvone Attenuated Doxorubicin Induced Cardiotoxicity In Vivo and Potentiated Its Anticancer Toxicity In Vitro |
| - | in-vivo, | BC, | MCF-7 | - | in-vivo, | Nor, | H9c2 |
| 6531- | CRV, | D-carvone attenuates LPS-induced acute lung injury via TLR4/NF-κB and Nrf2/HO-1 signaling pathways in rats |
| - | in-vivo, | Nor, | NA |
| 6530- | CRV, | Monoterpenes as Anticancer Therapeutic Agents |
| - | Review, | Var, | NA |
| 6529- | CRV, | D-Carvone Attenuates CCl4-Induced Liver Fibrosis in Rats by Inhibiting Oxidative Stress and TGF-ß 1/SMAD3 Signaling Pathway |
| - | in-vivo, | Nor, | NA |
| 6528- | CRV, | D-carvone inhibits growth, migration, cell cycle at G0/G1 phase and induces apoptosis in A431 cells by disrupting mitochondrial membrane potential |
| - | in-vitro, | Melanoma, | A431 |
| 6526- | CRV, | Multi-targeted effects of D-carvone against Non-Small Cell Lung Cancer (NSCLC): A network pharmacology-based study |
| - | Review, | NSCLC, | NA |
| 6525- | CRV, | D-carvone induced ROS mediated apoptotic cell death in human leukemic cell lines (Molt-4) |
| - | in-vitro, | AML, | NA |
| 6524- | CRV, | d-Carvone inhibits the JAK/STAT3 signaling pathway and induced the apoptotic cell death in the human gastric cancer AGS cells |
| - | in-vitro, | GC, | AGS |
| 6523- | CRV, | Anticancer effects of Carvone in myeloma cells is mediated through the inhibition of p38 MAPK signalling pathway, apoptosis induction and inhibition of cell invasion |
| - | NA, | Melanoma, | NA |
| 6522- | CRV, | l-carvone decreases breast cancer cells adhesion, migration, and invasion by suppressing FAK activation |
| - | in-vivo, | Var, | NA |
| 6521- | CRV, | L-carvone induces p53, caspase 3 mediated apoptosis and inhibits the migration of breast cancer cell lines |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 6520- | CRV, | Health Benefits and Pharmacological Properties of Carvone |
| - | Review, | Nor, | NA |
| 6176- | Cu, | Copper Oxide Nanoparticles Induced Mitochondria Mediated Apoptosis in Human Hepatocarcinoma Cells |
| - | in-vitro, | Liver, | HepG2 |
| 6177- | Cu, | Toxicity of copper oxide nanoparticles: a review study |
| - | Review, | Nor, | NA |
| 6171- | Cu, | Copper in the tumor microenvironment and tumor metastasis |
| - | Review, | Var, | NA |
| 6170- | Cu, | Copper induces cell death by targeting lipoylated TCA cycle proteins |
| - | in-vitro, | Var, | NA |
| 6182- | Cu, | Role of cuproptosis in digestive system tumors (Review) |
| - | Review, | Var, | NA |
| 6183- | Cu, | Copper(II) oxide nanoparticles penetrate into HepG2 cells, exert cytotoxicity via oxidative stress and induce pro-inflammatory response |
| - | in-vitro, | Liver, | HepG2 |
| 1601- | Cu, | The copper (II) complex of salicylate phenanthroline induces immunogenic cell death of colorectal cancer cells through inducing endoplasmic reticulum stress |
| - | in-vitro, | CRC, | NA |
| 1642- | Cu, | HCAs, | Copper-assisted anticancer activity of hydroxycinnamic acid terpyridine conjugates on triple-negative breast cancer |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | Nor, | L929 |
| 1639- | Cu, | HCAs, | Green synthesis of copper oxide nanoparticles using sinapic acid: an underpinning step towards antiangiogenic therapy for breast cancer |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 1604- | Cu, | Targeting copper metabolism: a promising strategy for cancer treatment |
| - | Review, | NA, | NA |
| 1603- | Cu, | BP, | SDT, | Glutathione Depletion-Induced ROS/NO Generation for Cascade Breast Cancer Therapy and Enhanced Anti-Tumor Immune Response |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 1602- | Cu, | A simultaneously GSH-depleted bimetallic Cu(ii) complex for enhanced chemodynamic cancer therapy† |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | 4T1 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HepG2 |
| 1600- | Cu, | Cu(II) complex that synergistically potentiates cytotoxicity and an antitumor immune response by targeting cellular redox homeostasis |
| - | Review, | NA, | NA |
| 1599- | Cu, | Copper in tumors and the use of copper-based compounds in cancer treatment |
| - | Review, | NA, | NA |
| 1569- | Cu, | Copper Nanoparticles as Therapeutic Anticancer Agents |
| - | Review, | NA, | NA |
| 1570- | Cu, | Development of copper nanoparticles and their prospective uses as antioxidants, antimicrobials, anticancer agents in the pharmaceutical sector |
| - | Review, | NA, | NA |
| 1571- | Cu, | Copper in cancer: From pathogenesis to therapy |
| - | Review, | NA, | NA |
| 1572- | Cu, | Recent Advances in Cancer Therapeutic Copper-Based Nanomaterials for Antitumor Therapy |
| - | Review, | NA, | NA |
| 1595- | Cu, | The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy |
| - | Review, | NA, | NA |
| 1598- | Cu, | Targeting copper in cancer therapy: 'Copper That Cancer' |
| - | Review, | NA, | NA |
| 1597- | Cu, | Anticancer potency of copper(II) complexes of thiosemicarbazones |
| - | Review, | NA, | NA |
| 1596- | Cu, | CDT, | Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review |
| - | Review, | NA, | NA |
| 1590- | Cuc, | ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism |
| - | Review, | NA, | NA |
| 6187- | Cuc, | Cucurbitacin I inhibits STAT3, but enhances STAT1 signaling in human cancer cells in vitro through disrupting actin filaments |
| - | in-vitro, | Lung, | A549 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid